It's Complicated

Picking stocks isn't easy. Take Amicus Therapeutics, Inc.(NASDAQ:FOLD) for example. Earlier this week it popped up on our radar due to increased investments by Glaxo, increasingly strong technical support, and increasing volume. All signs pointed to go until they announced a late stage study of the drug migalastat HCI didn't meet its primary goal. The stock dropped significantly although it was still up 67% this year.